| Bioactivity | Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes[1]. | ||||||||||||
| Target | Glucokinase | ||||||||||||
| In Vivo | Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats[2. Animal Model: | ||||||||||||
| Name | Dorzagliatin | ||||||||||||
| CAS | 1191995-00-2 | ||||||||||||
| Formula | C22H27ClN4O5 | ||||||||||||
| Molar Mass | 462.93 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes [2]. Wang P, et al. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. J Diabetes Res. 2017;2017:5812607. |
Dorzagliatin
CAS: 1191995-00-2 F: C22H27ClN4O5 W: 462.93
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell func
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.